For example , mammography screening does not seem to create anxiety in women who are given a clear result after a mammogram .
The incidence of breast cancer and mortality increases with age , and the GDG extrapolated that the absolute health benefits are greater in women aged 45 to 49 than those aged 40 to 44 years .
However , for the 45- to 49-year age group , the higher breast cancer incidence and mortality compared with women between the ages of 40 and 44 , as well as observational evidence showing a greater benefit in this age group ( 33 ) , led the GDG to judge that the balance of health effects probably favors screening , although the required re sources for screening likely differ across setting s ( 34 , 35 ) .
Other EtD criteria also were generally in favor of implementing organized mammography screening in this age group .
Despite intensified efforts by the European Council since 2003 , the implementation of organized , population -based mammography screening is not uniform across Europe and depends greatly on the policies in place in different countries , the organization of health care , and available re sources ( 1 ) .
Since the last edition of the European Guidelines on Breast Cancer Screening and Diagnosis was published in 2006 ( 2 ) , new evidence regarding breast cancer and innovation in guideline methodology prompted the European Commission Initiative on Breast Cancer ( ECIBC ) to develop new evidence -based recommendations ( in short , the European Breast Guidelines ) .
These guidelines inform women , health professionals , and policymakers about important questions related to organized mammography screening and breast cancer diagnosis , but recommendations may apply in context s in which organized screening programs are not in place .
Women generally consider these undesirable effects acceptable ( low certainty of evidence ) , and a systematic review suggested that women place a relatively low value on the psychosocial and physical effects of false-positive results and overdiagnosis ; however , some studies raised concerns about whether women fully underst and the result ing implication s ( 15 ) .
How Often Should Women Attend an Organized Mammography Screening Program ?
Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study
Abstract Objective To assess the performance of one-view digital breast tomo synthesis ( DBT ) in breast cancer screening . Methods The Malmö Breast Tomo synthesis Screening Trial is a prospect i ve population -based one-arm study with a planned inclusion of 15000 participants ; a r and om sample of women aged 40–74 years eligible for the screening programme . This is an explorative analysis of the first half of the study population ( n = 7500 ) . Participants underwent one-view DBT and two-view digital mammography ( DM ) , with independent double reading and scoring . Primary outcome measures were detection rate , recall rate and positive predictive value ( PPV ) . McNemar 's test with 95 % confidence intervals was used . Results Breast cancer was found in sixty-eight women . Of these , 46 cases were detected by both modalities , 21 by DBT alone and one by DM alone . The detection rate for one-view DBT was 8.9/1000 screens ( 95 % CI 6.9 to 11.3 ) and 6.3/1000 screens ( 4.6 to 8.3 ) for two-view DM ( p < 0.0001 ) . The recall rate after arbitration was 3.8 % ( 3.3 to 4.2 ) for DBT and 2.6 % ( 2.3 to 3.0 ) for DM ( p < 0.0001 ) . The PPV was 24 % for both DBT and DM . Conclusion Our results suggest that one-view DBT might be feasible as a st and -alone screening modality . Key Points• One-view DBT as a st and -alone breast cancer screening modality has not been investigated . • One-view DBT increased the cancer detection rate significantly . • The recall rate increased significantly but was still low . • Breast cancer screening with one-view DBT as a st and -alone modality seems feasible
For example , mammography screening does not seem to create anxiety in women who are given a clear result after a mammogram .
The incidence of breast cancer and mortality increases with age , and the GDG extrapolated that the absolute health benefits are greater in women aged 45 to 49 than those aged 40 to 44 years .
However , for the 45- to 49-year age group , the higher breast cancer incidence and mortality compared with women between the ages of 40 and 44 , as well as observational evidence showing a greater benefit in this age group ( 33 ) , led the GDG to judge that the balance of health effects probably favors screening , although the required re sources for screening likely differ across setting s ( 34 , 35 ) .
Other EtD criteria also were generally in favor of implementing organized mammography screening in this age group .
Despite intensified efforts by the European Council since 2003 , the implementation of organized , population -based mammography screening is not uniform across Europe and depends greatly on the policies in place in different countries , the organization of health care , and available re sources ( 1 ) .
Since the last edition of the European Guidelines on Breast Cancer Screening and Diagnosis was published in 2006 ( 2 ) , new evidence regarding breast cancer and innovation in guideline methodology prompted the European Commission Initiative on Breast Cancer ( ECIBC ) to develop new evidence -based recommendations ( in short , the European Breast Guidelines ) .
These guidelines inform women , health professionals , and policymakers about important questions related to organized mammography screening and breast cancer diagnosis , but recommendations may apply in context s in which organized screening programs are not in place .
Women generally consider these undesirable effects acceptable ( low certainty of evidence ) , and a systematic review suggested that women place a relatively low value on the psychosocial and physical effects of false-positive results and overdiagnosis ; however , some studies raised concerns about whether women fully underst and the result ing implication s ( 15 ) .
How Often Should Women Attend an Organized Mammography Screening Program ?